Skip to Content


In the US, Sargramostim (sargramostim systemic) is a member of the drug class colony stimulating factors and is used to treat Aplastic Anemia, Bone Marrow Transplantation, Bone Marrow Transplantation - Failure or Engraftment Delay, Bone Marrow Transplantation - Myeloid Reconstruction and Neutropenia Associated with Chemotherapy.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories


Colony stimulating factor, granulocyte-macrophage, GM-CSF

Chemical Name

23-L-Leucinecolony-stimulating factor 2 (human clone pHG25 protein moiety)

Foreign Names

  • Sargramostimum (Latin)
  • Sargramostim (German)
  • Sargramostim (French)
  • Sargramostim (Spanish)

Generic Names

Brand Name

  • Leucomax
    Yousuf Mahmood Husain, Bahrain

International Drug Name Search


BANBritish Approved Name
DCFDénomination Commune Française
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.